MA5-27002

antibody from Invitrogen Antibodies

Targeting: MARK4 FLJ90097, KIAA1860, MARKL1, Nbla00650, PAR-1D

Western blot (Data presented on provider website)

Immunohistochemistry (Data presented on provider website)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

MA5-27002

Provider

Invitrogen Antibodies

Product name

MARK4 Monoclonal Antibody (OTI9B7)

Antibody type

Monoclonal

Antigen

Recombinant protein fragment

Reactivity

Human

Host

Mouse

Isotype

IgG

Antibody clone number

OTI9B7

Vial size

100 µL

Concentration

1 mg/mL

Storage

-20° C, Avoid Freeze/Thaw Cycles

References

Submitted references

Discovery of 4-(2-(dimethylamino)ethoxy)benzohydrazide derivatives as prospective microtubule affinity regulating kinase 4 inhibitors.

Khan NS, Khan P, Inam A, Ahmad K, Yousuf M, Islam A, Ali S, Azam A, Husain M, Hassan MI
RSC advances 2020 May 26;10(34):20129-20137

---

Rosmarinic Acid Exhibits Anticancer Effects via MARK4 Inhibition.

Anwar S, Shamsi A, Shahbaaz M, Queen A, Khan P, Hasan GM, Islam A, Alajmi MF, Hussain A, Ahmad F, Hassan MI
Scientific reports 2020 Jun 25;10(1):10300

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Inhibition studies of MARK4 with selected hydrazone derivatives. (A) Dose-response curve for % hydrolysis of ATP shows the effect of increasing concentrations of compound H4 and H19 on ATPase activity of MARK4. Released phosphate was quantified using standard phosphate curve. (B) Representative expression profile of MARK4 and p-tau in compound H4/H19 treated MCF-7 cells with respect to control. Immunoblotting studies were performed after stipulated time treatment of respective compound and showed that treatment of cells with compound H4/H19 decreases the protein levels of MARK4 and p-tau.